January 29, 2023


News and research before you hear about it on CNBC and others. Claim your 1 week free trial StreetInsider Premium here.


BOSTON & NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogeneic cell-based product for solid tumors, announced today known has entered into an exclusive license agreement with the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) in New York, NY for the development and worldwide commercialization rights relating to intellectual property relating to the differentiation of the strongest immune cells from stem cells and large cells -Manufacturing on a scale. Under the terms of the agreement, Cell BioEngines will leverage Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies such as B. Subtypes of dendritic cells (DC), NK cells and macrophages that were previously inaccessible to cancer patients.

The licensed technology is based on discoveries made by Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research at Icahn Mount Sinai, member of the Tisch Cancer Institute at Mount Sinai and member of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center along with Sreekumar Balan, PhD, Assistant Professor of Medicine (Hematology and Medical Oncology) at the Bhardwaj Laboratory at Icahn Mount Sinai. Under the terms of the agreement, Icahn Mount Sinai is eligible for an undisclosed upfront payment and additional milestones based on development, regulatory and commercial milestones.

“Cell BioEngines is truly honored and excited about this opportunity to advance the discovery of Icahn Mount Sinai to bring great hope to people living with cancer and to position Cell BioEngines as a key player in the field of immune cell-based therapeutics,” said Ajay Vishwakarma, DMD, MSc, MBA, Founder and CEO of Cell BioEngines Inc.

“The technology platform developed in Nina’s lab essentially encompasses the incredible complexity of discovering single immune cell signatures in the tumor microenvironment, builds on my previous research conducted at Harvard Medical School/Broad Institute and allows us to differentiate the strongest immune clusters and produce large numbers of cellular states that are spatially stable and chemically configured to activate a robust anticancer response,” he added.

Image 1

“We are excited about the broad product potential that the technology platform can offer to target multiple solid tumors and benefit many people around the world. And certain immune cells like dendritic cells or natural killer cells are so rare that it’s not even easy to isolate the broad cell types, let alone the specific cell states,” said Alexey Bersenev, MD, PhD, Laboratory Director of Advanced Cell Therapy on Yale New Haven Hospital, Co-Founder and Chief Technology Officer of Cell BioEngines Inc. Dr. Bersenev was previously involved in transferring the manufacturing process of the first commercial CAR-T cell product, Kymriah, from the University of Pennsylvania to Novartis.

Cell BioEngines’ primary product focus is on stimulating the adaptive immune system of patients with a DC-based therapeutic cancer vaccine now known to enhance response in treatment-naïve and immunotherapy patients. Although CAR-T cells can be effective in blood cancers with identifiable tumor-specific surface antigens, targeting a broader panel of anonymous antigens and priming of new tumor-reactive T cells are clear cell-based advantages of cancer vaccines in solid tumors.

“We are pleased that the efficacy of conventional type I dendritic cell subsets (cDC1), a non-redundant cell subset in antitumor immunity, is being evaluated in the clinic for the first time to treat cancer patients,” said Dr. Bhardwaj. “Our immune cell generation platform can generate billions of functional dendritic cell subtypes and provide an option for the development of commercial cellular vaccines for cancer immunotherapy,” said Dr. Balan, who developed the technology with Dr. invented Bhardwaj.

About Cell BioEngines, Inc

Cell BioEngines, Inc is an innovative biopharmaceutical company focused on democratizing access to cell-based immunotherapy product candidates for cancer patients. The business strategy is to develop its proprietary platform technology for the identification, cell differentiation and scalable manufacturing of specific immune cell states with clinical potential. Through this approach, the Company has created a pipeline of development-stage assets for revenue streams.

Large-scale generation of specific cDC1 cells for cancer immunotherapy from hematopoietic stem cells is based on technology developed by Mount Sinai Faculty and licensed to Cell BioEngines. Mount Sinai has a financial interest in Cell BioEngines.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally recognized for its excellence in research, education and clinical care programs. It is the sole academic partner for the eight-person hospitals* of the Mount Sinai Health System, one of the largest academic health care systems in the United States, serving a large and diverse patient population.

Icahn Mount Sinai ranks 14th nationwide for funding from the National Institutes of Health (NIH) and ranks in the 99th percentile of research dollars per investigator according to the Association of American Medical Colleges. Icahn Mount Sinai has a talented, productive and successful faculty. Mount Sinai’s technology transfer office, one of the largest in the country, works with educators and trainees to pursue optimal commercialization of intellectual property and ensure that Mount Sinai’s discoveries and innovations are translated into healthcare products and services available to the public benefit. Icahn Mount Sinai’s commitment to pioneering science and clinical care is reinforced with academic affiliations that complement and complement the school’s programs.

Through Mount Sinai Innovation Partners (MSIP), the healthcare system facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. In addition, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border of the Upper East Side and East Harlem, and classroom instruction takes place on a campus overlooking Central Park. Icahn Mount Sinai’s location provides many opportunities to interact with and care for diverse communities. Learning extends well beyond the confines of our physical campus to the eight hospitals of the Mount Sinai Health System, our academic partners, and worldwide.

————————————————– —–

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai morning side; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Contact

Mark Joubert, JD Chief Legal Officer Cell BioEngines, Inc

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6108b363-80e6-4105-a7b0-f00da6f8b64f

Contact : [email protected]

Primary logo

dr Nina Bhardwaj from Mount Sinai and Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines

dr Nina Bhardwaj from Mount Sinai and Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines

Source: Cell BioEngines, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *